| Withdrawn | 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma NCT04832438 | Actuate Therapeutics Inc. | Phase 2 |
| Recruiting | DESTINY-PANTUMOUR04 NCT07124000 | AstraZeneca | — |
| Recruiting | Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) NCT06923826 | National University Hospital, Singapore | Phase 2 |
| Recruiting | A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers NCT06805617 | Glenn J. Hanna | Phase 2 |
| Recruiting | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors NCT06695845 | Jazz Pharmaceuticals | Phase 2 |
| Completed | Enhanced Assistance During Radiotherapy for Unmet Essential Needs NCT06582849 | Washington University School of Medicine | N/A |
| Not Yet Recruiting | Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland C NCT06091878 | Royal Marsden NHS Foundation Trust | — |
| Recruiting | Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers NCT05553782 | Brigham and Women's Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC NCT05898373 | Peking Union Medical College | Phase 1 / Phase 2 |
| Active Not Recruiting | Amivantamab in Adenoid Cystic Carcinoma NCT05074940 | Trisha Wise-Draper | Phase 2 |
| Recruiting | The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers NCT05483374 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Completed | Survival With Patients Treated With Salivary Gland Cancer NCT05390294 | Clinical Center of Vojvodina | — |
| Active Not Recruiting | 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma NCT05010629 | Glenn J. Hanna | Phase 2 |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Recruiting | Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas NCT04620187 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NCT04140526 | OncoC4, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers NCT04209660 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients NCT04291300 | Radboud University Medical Center | Phase 2 |
| Completed | Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY) NCT05694819 | National Cancer Center Hospital East | Phase 2 |
| Terminated | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRP NCT04249947 | Poseida Therapeutics, Inc. | Phase 1 |
| Unknown | PSMA-PET Imaging Before and After ADT in Advanced SDC Patients NCT04214353 | Radboud University Medical Center | N/A |
| Active Not Recruiting | APG-115 in Salivary Gland Cancer Trial NCT03781986 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Unknown | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients NCT03924466 | Universitair Ziekenhuis Brussel | Phase 2 |
| Terminated | Cabozantinib in Advanced Salivary Gland Cancer Patients NCT03729297 | Radboud University Medical Center | Phase 2 |
| Completed | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Ge NCT03602079 | Klus Pharma Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors NCT03360890 | University of Chicago | Phase 2 |
| Completed | PSMA-PET Imaging for Advanced ACC/SDC NCT03319641 | Radboud University Medical Center | N/A |
| Completed | Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer NCT03172624 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Cell-free Tumor DNA in Head and Neck Cancer Patients NCT03942380 | Christian von Buchwald | N/A |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) NCT02628067 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Androgen Deprivation Therapy in Advanced Salivary Gland Cancer NCT01969578 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Unknown | Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland NCT02401763 | National Taiwan University Hospital | — |
| Completed | A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes NCT02069730 | University Health Network, Toronto | N/A |
| Unknown | Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Mu NCT05008237 | Samsung Medical Center | Phase 2 |
| Unknown | Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland C NCT02048254 | Peking University | Phase 3 |
| Terminated | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer NCT02042885 | Otsuka Novel Products GmbH | Phase 1 / Phase 2 |
| Recruiting | Integrated Cancer Repository for Cancer Research NCT02012699 | University of Nebraska | — |
| Completed | Activity of Sorafenib in Salivary Gland Cancer NCT01703455 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Completed | Stereotactic Body Radiotherapy for Head and Neck Tumors NCT01344356 | Mercy Research | Phase 4 |
| Completed | A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands NCT00886132 | University Health Network, Toronto | Phase 2 |
| Completed | Iressa Study in Patients With Salivary Gland Cancer NCT00509002 | M.D. Anderson Cancer Center | Phase 2 |